5 unchanged sentences
Amended and Restated Bylaws
+Added: Second Amendment to the Exclusive Janssen License and Collaboration Agreement, dated July 27, 2021, by and between Protagonist Therapeutics, Inc.
+Added: and Janssen Biotech, Inc.
+Added: Arbitration Resolution Agreement, dated August 4 th , 2021, by and among Protagonist Therapeutics, Inc.
+Added: and Zealand Pharma, A/S.
+Added: Second Amendment to Lease, dated August 10, 2021, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center, LP as Landlord.
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
10 unchanged sentences
+ Filed herewith
+Added: † Confidential treatment has been granted for a portion of this exhibit.
* This certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Protagonist Therapeutics, Inc.
2 unchanged sentences
PROTAGONIST THERAPEUTICS, INC.
−Removed: August 4, 2021
+Added: November 3, 2021
/s/ Dinesh V.
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 4, 2021
+Added: November 3, 2021
/s/ Don Kalkofen
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.